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Abstract
Background: The cellular activity of many factors and pathways is required to execute the complex replication
cycle of the human immunodeficiency virus type 1 (HIV-1). To reveal these cellular components, several extensive
RNAi screens have been performed, listing numerous ‘HIV-dependency factors’. However, only a small overlap
between these lists exists, calling for further evaluation of the relevance of specific factors to HIV-1 replication and
for the identification of additional cellular candidates. TBC1D20, the GTPase-activating protein (GAP) of Rab1,
regulates endoplasmic reticulum (ER) to Golgi trafficking, was not identified in any of these screens, and its
involvement in HIV-1 replication cycle is tested here.
Findings: Excessive TBC1D20 activity perturbs the early trafficking of HIV-1 envelope protein through the secretory
pathway. Overexpression of TBC1D20 hampered envelope processing and reduced its association with detergent-
resistant membranes, entailing a reduction in infectivity of HIV-1 virion like particles (VLPs).
Conclusions: These findings add TBC1D20 to the network of host factors regulating HIV replication cycle.
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Findings
Numerous host factors regulate, directly and indirectly,
different steps of HIV-1 infection. To reveal these fac-
tors, several extensive RNAi screens have been per-
formed, listing over a thousand proteins [1-5].
Surprisingly, there is only a small overlap between these
lists, calling for further evaluation of the relevance of
specific factors to HIV-1 replication [6,7]. The small
GTPase Rab1 has been marked in one of these screens
as a putative HIV-dependency factor [1]. Here we iden-
tified TBC1D20, a specific GAP of this Rab [8,9], as a
new host factor that regulates HIV replication.
Rab1, which cycles between active GTP-bound and
inactive GDP-bound forms [10], and is present as
Rab1a/b isoforms, regulates the early secretory pathway
by controlling ER to Golgi traffic [11]; yet, unconven-
tional Rab1-independent secretion pathway(s) have also
been described [12-14]. TBC1D20, a Rab1-GAP, inacti-
vates Rab1 through the stimulation of GTP hydrolysis;
accordingly, TBC1D20 overproduction blocks Rab1-
mediated ER-to-Golgi transport [8,9]. The utilization of
the Rab1-dependent secretory pathway by HIV-1 and
the influence of TBC1D20/Rab1 axis on its infectivity
remain unexplored.
The maturation and assembly of HIV-1 envelope
(Env) occur along the secretory pathway. Env matura-
tion requires post-translational modifications, including
the initial acquisition of high-mannose sugar trees that
occurs within the ER. Subsequent maturation steps such
as the trimming of this sugar-tree, acquisition of differ-
ent sugars that modify Env apparent molecular weight
(MW) and the furin-mediated cleavage of gp160 precur-
sor to gp120 and gp41, require Env transport through
posterior secretory pathway compartments [15]. Finally,
targeting to specific domains of the plasma membrane is
required for efficient assembly of Env into nascent
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specific factors and secretory pathways involved in these
processes remains unknown. To investigate if Env
maturation and trafficking are regulated by TBC1D20
and occur via Rab1-dependent pathway, we exploited
the effect induced by imbalanced expression of
TBC1D20 on Rab1-mediated transport, and probed for
the infectivity of HIV-1 VLPs in such conditions. In pre-
vious studies, it was shown that TBC1D20 is a negative
regulator of the ER-to-Golgi traffic of a temperature
sensitive mutant of the envelope glycoprotein of the
vesicular stomatitis virus (VSV-G) in HeLa cells [8,9].
To expand this finding to the present experimental sys-
tem, 293T cells were co-transfected with plasmids
encoding for VSV-G (2.5 μg), the HIV-1 Gag-Pol
[ΔR8.2;[18] 7.5 μg], a retroviral vector encoding GFP
[pHR’CMV-GFP [19]; 10 μg], and Myc-tagged TBC1D20
[pMyc-TBC1D20 [9]; 10 μg]. A Myc-tagged catalytically
inactive form of TBC1D20 [R105A [8,9]; 10 μg)], or an
empty vector [pCMV-Myc (Clontech); 10 μg] served as
controls. Supernatants were collected 48 h post transfec-
tion and equal amounts of VLPs, normalized by RT exo-
genous assay [20], were used to infect naïve HeLa TZM-
bl cells, expressing CD4, CXCR4 and CCR5 molecules
[21]. Of note, TZM-bl cells carry the LTR-driven firefly
luciferase as well as the b-galactosidase reporter genes
to monitor HIV infection; however, we used the GFP
reporter in pHR’CMV-GFP vector to quantify infection
levels since this vector does not express the Tat protein,
which is essential for luciferase and b-galactosidase acti-
vation in infected TZM-bl cells; and as GFP expression
enables the quantification of large numbers of infected
cells through fluorescence-activated cell sorting (FACS)
analysis. Figure 1A shows that in accord with a block to
VSV-G trafficking, overexpression of TBC1D20
decreased the number of infected cells (GFP+) to 20%
of the control. To address if HIV Env is analogously
regulated, a similar experiment was performed with HIV
E n v[ J R C S F[ 2 2 ] ;2 . 5μg ]( F i g u r e1 B ) .H e r et o o ,
TBC1D20 overexpression decreased the infectivity of
VLPs suggesting that VSV-G and HIV Env traffic
through a Rab1-sensitive pathway.
To further characterize the source of this decrease,
293T cells were transfected with ΔR8.2 (1 μg), JRCSF
(1.5 μg) together with pMyc-TBC1D20, R105A or
pCMV-Myc (3 μg each). Lysates from the transfected
cells and virions purified from the culture supernatants
by ultracentrifugation through a 25% sucrose cushion
were subjected to Western blot analysis (Figure 2). Simi-
lar capsid (CA) levels were observed in all the samples,
suggesting that TBC1D20 overexpression did not reduce
VLPs production. In contrast, TBC1D20 overexpression
greatly decreased the levels of gp160 and gp41 in VLPs
(Figure 2A; ‘Virion Pellets’ panel): the average levels of
Env proteins, measured by densitometry in three inde-
pendent experiments, was 18% ± 7 (gp160) and 0.8% ±
0.5 (gp41), compared to the 100% of the empty vector
control. Overexpression of R105A resulted in a smaller
reduction (Figure 2A; ‘Virion Pellets’ panel), with aver-
age levels of 80% ± 5 (gp160) and 39% ± 17 (gp41). The
reduction in Env virion levels observed for R105A may
be explained by the fact that although catalytic inactive,
it is still able to interact with other cellular proteins
such as the reticulon [8]. This latter protein is localized
to the ER, and evidence exist for its influence on ER-to-
Golgi trafficking, vesicle formation and membrane mor-
phogenesis [23]. Thus, R105A overexpression may still
affect Env levels to some extent in a Rab1-independent
manner. In any case, the reduction in the virion Env
levels, observed for either TBC1D20 or R105A expres-
sion, is in agreement with the decrease in VLPs infectiv-
ity (Figure 1B). TBC1D20 overexpression resulted in a
faster migrating form of gp41 (Figure 2A; ‘Cell Extracts’
panel), likely reflecting altered glycosylation (see below).
This change in migration was not evident for gp160, as
expected for ER-localized protein. While TBC1D20-
overexpression altered the migration of gp41 in all
experiments (n = 15), in some experiments (n=7) a
small reduction in gp41 level was also observed,
Figure 1 Overexpression of TBC1D20 decreases HIV-1 VLPs
infectivity. HIV-1 VLPs, pseudotyped with either VSV-G (A) or JRCSF
(B) glycoproteins, were generated in 293T cells (~5 × 106 cells/60
mm plate), overexpressing TBC1D20, R105A, or empty vector. HeLa
TZM-bl cells were infected with equal amounts of these VLPs and
the number of GFP
+ cells per 5,000 cells was determined by FACS.
The data are represented as the mean ± the standard error of the
mean (SEM, n = 3).
Nachmias et al. Retrovirology 2012, 9:7
http://www.retrovirology.com/content/9/1/7
Page 2 of 7probably reflecting a reduction in gp160 cleavage (see
for example the LAI Env in Figure 2B, where gp160
level was higher but gp41 level was reduced, in the
TBC1D20 sample compared to the controls). Overall,
these data suggest that enhanced TBC1D20 activity
caused abnormal Env processing and reduced its incor-
poration into nascent virions, correlating with the
reduced infectivity of such particles.
Because of the profound effect of TBC1D20 overex-
pression on gp41 migration (JRCSF strain), we expanded
this analysis to the JRFL (R5 strain) and LAI (X4 strain)
envelope proteins [22,24,25] and to the VSV-G.
TBC1D20 overexpression resulted in abnormal migra-
tion of all these proteins (Figure 2B). This result is in
line with TBC1D20 effect on ER-to-Golgi trafficking of
VSV-G [8,9] and with the reduced infectivity of HIV-1
VLPs pseudotyped with VSV-G (Figure 1A). Overall,
these results indicate the generality of TBC1D20 activity
on the cellular processing of the envelope glycoproteins
of these viruses. In accord with this conclusion,
TBC1D20 overexpression also resulted in abnormal
migration of the transforming growth factor beta recep-
tor II (TGFb receptor II) - a glycosylated cellular protein
that traffics through the secretory pathway to the plasma
membrane (data not shown).
The above effect of TBC1D 2 0o nt h em i g r a t i o no f
envelope glycoproteins is expected to reflect a lack of
R a b 1a c t i v i t y-t h et a r g e to fT B C 1 D 2 0 .W en e x te x a m -
ined if direct modulations of Rab1 activity will similarly
affect gp41 migration. We transfected cells with the
JRCSF Env and Gag-Pol proteins (as in Figure 2A) and
either TBC1D20, R105A, Rab1a, Rab1b, constitutively-
active Rab1b (Q67L) [26] or the dominant negative
(DN) forms of Rab1a (N124I) or Rab1b (N121I) [11].
All of these proteins were expressed as GFP fusions [9],
accordingly a GFP only negative control was used. All
treatments, except for the negative controls (R105A or
GFP), induced the aberrant migration of gp41 (Figure
2C). The DN activity of N124I and N121I, similar to
TBC1D20 overexpression, reduces Rab1 function and
thus the aberrant migration of gp41 is expected. Surpris-
ingly, overexpression of Rab1a, Rab1b or Q67L, which
enhances Rab1 activity, also resulted in abnormal gp41
migration. An explanation for this might be the observa-
tion that excesses of Rab1 activity increase ER-to-Golgi
transport [27], and this too may impair proper glycosy-
lation. Thus, a precise regulation of the Rab1/TBC1D20
axis may be necessary for proper gp41 processing.
Sugar modifications are indicative of protein traffick-
ing through specific compartments of the secretory
pathway [28]. Since TBC1D20/Rab1 function in regulat-
ing ER-to-Golgi trafficking [8,9,11] and since Env is
heavily glycosylated [29], the observed aberrant migra-
tion of Env in SDS-PAGE for cells overexpressing
Figure 2 Overexpression of TBC1D20 alters the apparent MW
of Env and decreases its incorporation into VLPs. (A) HIV-1 VLPs,
pseudotyped with JRCSF envelope, were generated in 293T cells
(~2 × 106/well, 6-well plate) overexpressing the indicated GAPs
(TBC1D20 or R105A) or an empty vector. Cell extracts were prepared
from transfected cells and from virion pellets that were purified
from the supernatants of the transfected cultures. Western blot was
used to detect the expression of Env, Myc-tagged GAPs, CA and
GAPDH, using monoclonal antibodies against gp41 [Chessie 8
hybridoma, [37]; Myc epitope (9E10 hybridoma); CA [183-H12-5C
hybridoma, [46]] and GAPDH (Chemicon, cat. #MAB374). (B) Identical
procedure was used to monitor the effect of overexpression of the
indicated GAPs on the apparent MW of gp41 (JRFL, LAI and JRCSF
strains) and VSV-G; and (C) to monitor this effect on JRCSF Env
upon overexpression of the indicated Rab forms. These forms were
expressed as GFP fusions [9], where the parental pEGFP-C1 plasmid
(Clonetech), expressing the GFP alone, served as a negative control.
Antibodies against GFP (Convance, cat. #MMS-118R) and actin (MP
Biomedicals, cat. #69100) were used to detect protein expression.
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trafficking. To study this, we performed deglycosylation
sensitivity assays, as described [30]. 293T cells were
transfected as described in Figure 2 and lysed; the
extracts were treated with endoglycosidase H (EndoH),
which cleaves N-linked high-mannose oligosaccharides,
found on proteins located in the ER/cis Golgi [31]. SDS-
PAGE-immunoblot analysis of lysates of cells expressing
JRCSF Env, using anti-gp41 antibodies, yielded two
main forms of Env corresponding to gp160 and gp41
that appeared smeared, suggesting multiple glycosylated
forms of Env (see ‘empty vector’ and ‘R105A’ controls -
Figure 3A, lanes 1 and 5). To confirm that the broad
distribution of Env molecules stems from glycosylation,
we digested the cell lysates with Peptide:N-glycosidase F
(PNGase F), which removes all types of N-linked glyco-
sylation [32]. Indeed, this treatment resulted in the col-
lapse of the smears to distinct bands of approximately
96 and 39 kDa; matching the net MW of these proteins
(see controls - Figure 3B, lanes 9, 10, 13 and 14).
EndoH treatment resulted in a similar collapse of gp160
forms while failing to markedly alter the distribution of
majority of gp41 molecules (see controls - Figure 3A,
l a n e s1 ,2 ,5a n d6 ;‘EndoH-resistant gp41’). These
results are in accord with ER localization of gp160 as it
is mainly EndoH-sensitive and support the traffic of
gp41 up to the trans-Golgi network since it is both
furin-cleaved and EndoH-resistant [33]. These results
are also in line with previous studies that established
that the kinetics of EndoH-resistance closely parallel
those of Env cleavage [34]. Next, we addressed the effect
of TBC1D20 on Env glycosylation. While all Env forms
w e r ee q u a l l ys e n s i t i v et oP N G a s eF( F i g u r e3 B ,l a n e s1 1
and 12), and gp160 remained EndoH-sensitive (Figure
3A, lanes 3 and 4), a clear reduction in the apparent
MW of gp41 was observed both prior to, and following,
EndoH treatment (Figure 3A, lanes 3 and 4). Specifi-
cally, in untreated lysates a lower form of gp41 (~41
kDa) was observed; furthermore, in EndoH-treated
lysates the majority of gp41 collapsed to about 39 kDa,
suggesting EndoH sensitivity. These observations sup-
port the ER retention of Env upon TBC1D20 overex-
pression. The low but detectable level of EndoH-
sensitive gp41 present in TBCID20-expressing cells
may indicate the premature cleavage of gp160. This
may be the result of abnormal retention of furins in
the ER, resulting in untimely cleavage of gp160. Alter-
natively, the ER localization of cleaved Env may result
from its retrograde transport back into the ER.
Another explanation is that this form of EndoH-sensi-
tive gp41 may represent gp41 molecules that had nor-
mally proceeded through the Golgi yet retained high-
mannose oligosaccharide side chains, since it has been
shown that gp120 and gp41 contain both high-man-
nose (EndoH-sensitive) and terminally processed
(EndoH-resistant) carbohydrate chains [34]. In this
case, the presence of high-mannose side chains does
not necessarily indicate a pre-Golgi localization. How-
ever, even in this scenario, the fact that TBC1D20
overexpression resulted in almost a full elimination of
EndoH-resistant gp41 forms (Figure 3A, compare lanes
1 and 3) suggests TBC1D20-mediated impairment of
Env trafficking. Of note, the anti-gp41 Chassie anti-
body also detected ~55 kDa bands in PNGase F-trea-
ted extracts (Figure 3B). In principle, these bands can
correspond to deglycosylated from of gp120 since N-
linked glycans comprise about 50% of the mass of
gp120 [35] and as PNGase F treatment shifts gp120
MW to ~60 kDa [36]. Indeed, these bands also reacted
with anti-gp120 antibody when the membrane was re-
probed (data not shown). However, since the Chassie
antibody does not react with gp120 (our observations
and see [37]), we cannot exclude the possibility that
Figure 3 TBC1D20 overexpression impairs proper HIV Env
glycosylation. Extracts (100 μg of total protein) of 2 × 10
6 293T
cells expressing HIV-1 Gag-Pol and JRCSF Env proteins, together
with either TBC1D20, or controls (R105A or empty vector), were
treated with (’+’) or without (’-’) EndoH (A) or PNGase F (B). Extracts
were examined by Western blot analysis using anti-gp41
monoclonal antibody, to detect gp160 and gp41.
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tein that is not related to HIV Env.
To achieve efficient assembly, Env proteins need to
localize to microdomains at the plasma membrane,
named detergent-resistant membranes (DRMs) [16,17].
The here-described TBC1D20-induced alterations of
Env trafficking are expected to reduce its localization at
these sites. To investigate this, we monitored the distri-
bution of gp41 between DRMs and soluble fractions in
cells overexpressing TBCID20, R105A (both fused to
GFP), or GFP alone, using equilibrium flotation centrifu-
gation [38]. Caveolin, expressed in 293T cells and loca-
lized to DRMs, served as a marker for DRMs-enriched
fractions [16,17]. 293T cells were transfected (as
described in Figure 2A, with four fold DNA amounts),
36 h post transfection the cultures were moved from 37°
C to 15°C for an additional 4 h to retain proteins in the
ER [39]. Then, cyclohexamide (50 μg/ml) was added to
inhibit protein synthesis, and the cultures were reincu-
bated at 37°C (for 8 h) to synchronize the ER exit of
proteins. Subsequently, cells were extracted at 4°C with
Triton X-100, and the lysates were separated on sucrose
gradients (Figure 4A). Fractions of the gradients were
analyzed by Western blotting, using anti-gp41 and anti-
caveolin antibodies (Figure 4B). This analysis revealed
that overexpression of TBC1D20, but not controls,
resulted in marked reduction in DRM-localized gp41
(Figure 4B; fractions 4-7), while the remaining gp41 was
localized to soluble fractions (Figure 4B; fractions 9-12,
boxed). The average ratio between gp41 levels in soluble
versus detergent-resistant fractions, calculated by densi-
tometry was approximately five times higher for
TBC1D20-overexpression, compared to the controls (n
= 3, Figure 4C). These results are in line with Env loca-
lization to the earlier membrane compartments of the
secretory pathway upon TBC1D20 overexpression (see
Figure 3); further suggesting that TBC1D20 overexpres-
sion reduces the trafficking of Env towards the assembly
sites at the plasma membrane. The residual Env levels
found in virions and DRMs upon TBC1D20 overexpres-
sion (Figure 2A and 4) could result from early Env tar-
geting to the plasma membrane, before TBC1D20
blockage and/or the outcome of residual Env trafficking
through an unconventional secretion pathway, induced
by ER stress [12,13].
Overall, TBC1D20 may affect virus replication cycle
either directly, as in the case of the hepatitis C virus
where interaction of TBC1D20 with the viral protein
NS5A is required for viral RNA replication [9,40]; or
indirectly, as described here for HIV-1 and recently for
herpes simplex virus [41], where TBC1D20 affects the
ER-trafficking of the viral envelope glycoproteins.
To summarize, here, we showed that enhancement of
TBC1D20 activity, a negative regulator of Rab1 function,
perturbs HIV-1 infectivity. This adds the TBC1D20/
Rab1 axis to other identified factors of the secretory
pathway that influence HIV replication cycle, such as
Rab5, 6a, 7, 9 and 11a, [1,42-45]; and places TBC1D20
in the network of host regulators of the late stages of
HIV infection.
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